Nucala (Mepolizumab)

Mepolizumab, the active ingredient in Nucala, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It selectively binds interleukin‑5, reducing eosinophil activity, and is indicated for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and chronic rhinosinusitis with nasal polyps in patients with elevated eosinophil counts.

GNH USA supplies Nucala as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering EU‑sourced product with full quality documentation.

Nucala is used in diseases driven by eosinophilic inflammation, targeting the IL‑5 pathway.

- Severe eosinophilic asthma: lowers the rate of asthma attacks, improves control and may reduce the need for oral corticosteroids in patients with elevated blood eosinophils. - Eosinophilic granulomatosis with polyangiitis (EGPA): contributes to disease remission, decreases vasculitic activity and reduces reliance on systemic steroids. - Chronic rhinosinusitis with nasal polyps: shrinks nasal polyps, relieves nasal congestion and improves sense of smell in individuals with eosinophilic inflammation.

Mepolizumab may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Headache - Upper respiratory tract infection - Fatigue

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions - Development of anti‑drug antibodies that may reduce efficacy - Immune‑mediated conditions such as vasculitis or eosinophilic pneumonia (rare)

Before initiating Nucala, clinicians should consider several precautionary measures to ensure safe use.

- Assess eosinophil count: confirm elevated eosinophils to justify therapy. - Screen for parasitic infections: treat any active helminth infection before starting. - Monitor for hypersensitivity: observe patients for signs of allergic reaction after each injection. - Use with caution in pregnancy: safety data are limited; weigh potential benefits against risks. - Avoid in patients with known hypersensitivity to mepolizumab or any excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepolizumab has a limited interaction profile, but certain combinations require attention.

Major Interactions (Avoid): - Live vaccines: concurrent administration may increase risk of infection; avoid using live vaccines while receiving mepolizumab. - Other IL‑5 targeting agents: combined use can lead to excessive immunosuppression.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., corticosteroids, azathioprine): may heighten infection risk, monitor patient closely. - Other monoclonal antibodies: assess for additive immunologic effects. - Cytochrome P450 substrates: no direct effect, but monitor clinical response as disease control may change.